id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-D-1245-0020,FDA,FDA-2015-D-1245,Guidance for Industry on Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System,Other,Guidance,2017-12-26T05:00:00Z,2017,12,2017-12-26T05:00:00Z,,2024-11-07T01:16:09Z,,1,0,0900006482d734ba
FDA-2015-D-1245-0019,FDA,FDA-2015-D-1245,Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System; Guidance for Industry; Availability,Notice,Notice of Availability,2017-12-26T05:00:00Z,2017,12,2017-12-26T05:00:00Z,,2017-12-26T16:51:11Z,2017-27786,0,0,0900006482d727c5